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Obesity and Elevated Plasma Leptin
Concentration in oMT1A-o Growth Hormone
Transgenic Mice
Anita M. Oberbauer,* Jonathan A. Runstadler,* James D. Murray,*† and Peter J. Havel‡
Abstract
OBERBAUER, A. M., JONATHAN A. RUNSTADLER,
JAMES D. MURRAY, AND PETER J. HAVEL. Obesity
and elevated plasma leptin concentration in oMT1A-o
growth hormone transgenic mice. Obes Res. 2001;9:51–58.
Objective: This study was undertaken to evaluate plasma
leptin concentration in the regulatable ovine metallothio-
nein-ovine growth hormone (oMT1a-oGH) transgenic (TG)
mouse model of obesity.
Research Methods and Procedures: Transgene stimulus
(zinc) was provided at 21 days of age to male and female
wild-type (WT) and TG mice. Plasma leptin concentrations
were measured by radioimmunoassay at 42, 63, 84, and 105
days of age and from inactivated TG mice at 84 and 105 days.
Results: WT and TG mice did not differ significantly in
plasma leptin concentration at any of the ages examined (42,
63, 84, and 105 days), although females showed consis-
tently higher plasma leptin concentrations than males re-
gardless of genotype throughout the duration of the study.
Male and female TG mice in which the transgene was
inactivated at 63 days had a 1.5-fold to 3.5-fold increase in
plasma leptin concentration over WT mice and continuously
activated TG mice at 84 and 105 days of age. The elevated
plasma leptin concentration seen in the inactivated TG mice
at 84 and 105 days of age reflects the .300% increase in
white adipose tissue seen in this model and correlated with
all adipose depot weights and overall body lipid at these
later ages. When plasma leptin was expressed per gram of
total body fat, the leptin adjusted for body lipid was signif-
icantly higher in WT mice than either continuously acti-
vated TG or activated and then inactivated TG groups.
Discussion: The inactivated TG mice in this study had
higher plasma leptin levels with increasing total body adi-
posity, but the relative proportion of circulating leptin, on a
total body lipid basis, was reduced when compared with the
WT mice. This reduction was also observed in activated TG
mice at the older ages. Although the absolute levels of
circulating leptin were elevated in the inactivated TG ani-
mals, the amount of leptin produced per gram of fat was
lowered. With the inactivation of the transgene, the leptin
remained depressed after the removal of the elevated growth
hormone. This represents a potential explanation for the
ensuing hypertrophy of the fat depots and the abnormal
phenotypic response of inactivated TG mice to elevated
plasma leptin concentrations resulting in the development
of obesity.
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Introduction
The adipocyte hormone leptin plays a direct role in the
control of body fat mass (1– 4) by regulating energy
intake and expenditure. Growth hormone (GH), which
has been studied since the 1920s, is also known to play a
role in a variety of physiological growth processes, in-
cluding fat metabolism (5). Leptin acts as a signal of
energy reserves stored as body fat and of recent energy
intake via changes in insulin secretion (6,7). In contrast,
GH is associated with metabolic processes that act to
limit the accumulation of body fat and promote the de-
velopment of lean body mass.
The transgenic (TG) mice used in this study are a
unique in vivo model for adipogenesis (8). They have
integrated in their genome an ovine metallothionein pro-
moter-driven ovine GH transgene tandem array (oMT1a-
oGH). Overexpression of this transgene construct can be
tightly controlled (8,9) such that when transgene expres-
sion is activated, circulating ovine GH levels rise to
.2000 ng/mL, whereas inactivation of transgene expres-
sion results in a marked decrease in circulating GH levels
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to ,75 ng/mL (8). Animals under the influence of acti-
vated transgene expression grow to mature weights that
are ;30% to 40% heavier than control mice. In addition,
although male mice normally grow at a faster rate than
females, the growth rate is equal under the influence of
the transgene. When the transgene is inactivated, both
genders exhibit an obese phenotype with white adipose
tissue (WAT) depots that are ;270% heavier (expressed
as percent of fasted body weight) than control animals
and an overall increase in total body lipid of 285% (8,10).
Furthermore, obesity in this model is not a transient
effect of the cessation of transgene expression because
the obesity persists and the increased body fat is reflected
in WAT hyperplasia and hypertrophy (8). The obese
phenotype occurs even when food intake is restricted,
indicating that metabolic changes related to the overexpression
of GH via transgene activation are responsible (10). Although
glucose concentrations in these animals are unaffected by
either transgene activation status or extent of obesity, circulat-
ing insulin concentrations are elevated 2-fold to 3-fold with
elevated GH and then gradually decline after the withdrawal of
the transgene stimulus, although never reaching control animal
values (8).
GH does not appear to directly control leptin expression
(11), but it may indirectly influence leptin expression
through its effect on whole-body metabolism. Leptin may
play a permissive role in controlling the release of GH from the
pituitary when adipose tissue stores are high. Rising plasma
leptin concentrations produce an increase of GH that can be
prevented by the administration of anti-leptin antibody to the
ventricular space of fed rats (12). Despite these clues, it re-
mains unclear how the elevated expression of GH affects the
pathway of adipocyte development and differentiation to pro-
duce the obese phenotype in the oMT1a-oGH TG model.
This investigation was undertaken to define further the
nature of the interaction between GH and leptin, hormones
that have an impact on the physiology of adipocyte devel-
opment, growth, and function. We wanted to determine
whether aberrant production of leptin in adipocytes plays a
role in the development of the obese phenotype. We know
that the increased GH expression induces adipogenesis in
this model. Using samples from a study published previ-
ously (8), we designed the present study to determine
whether the development of this obesity was due to a
dysregulation of leptin. Knowledge of the interaction be-
tween leptin and GH activity will aid in the development of
therapeutic regimes to modulate expression, receptor sensi-
tivity, and/or transport of these endocrine hormones to treat
obesity in both humans and animals.
Research Methods and Procedures
Experimental Design
Wild-type (WT) and TG mice for this experiment were
generated using a cross of WT females (C57BL/6 3 CBA)
and male mice hemizygous for the transgene (oMT1a-oGH)
(8). The GH transgene is expected to segregate into 50% of
the resulting offspring in these crosses. Litters were stan-
dardized to seven to nine pups at 1 day of age and all pups
were toe-notched at 10 days of age for identification and
genotyping.
All mice were housed in a facility approved by the
American Association for the Accreditation of Laboratory
Animal Care under conditions of constant temperature
(21 °C), humidity (55%), and light (14:10 hour light:dark
cycle). At 21 days, mice were weaned and placed two to a
cage by gender. All mice were fed Purina Laboratory Chow
no. 5008 (4.2 kcal/g gross energy; Purina Mills, St. Louis,
MO). Transgene expression was induced at weaning in the
TG animals by supplying 25 mM ZnSO4 in the drinking
water ad libitum; WT controls were also given 25 mM
ZnSO4 in drinking water ad libitum. Treatment groups
consisted of male and female groups of TG and WT mice
sampled at 42, 63, 84, and 105 days of age. At 63 days of
age, four new treatment groups were established by discon-
tinuing ZnSO4 in a subset of male and female WT and TG
animals. These new inactivated treatment groups were also
sampled at 84 and 105 days. At each age, six to eight mice
from each treatment group were fasted for 12 hours and
killed with CO2. Intracardial aspiration with a 22-gauge
needle was performed immediately after killing, and blood
was transferred to EDTA-containing tubes that were centri-
fuged for plasma collection. Plasma samples from each
mouse were stored at 280 °C until the leptin assay was
performed. All mice were sampled at the same time of day.
As described previously for the animals used in the present
study, adipose tissue depots, the right inguinal subcutane-
ous, the mesenteric, and right gonadal depots were individ-
ually dissected and weighed, with total body lipid deter-
mined by lipid extraction of the carcass (8).
Leptin Assay
Mouse plasma leptin was analyzed with a sensitive and
specific radioimmunoassay developed to measure mouse
leptin (13). Samples were run in duplicate. Coefficients of
variation average 7.1% within runs and 10.0% between runs
for this assay.
Statistical Analysis
Statistical analysis was performed with Statview for Win-
dows version 5.0.1 (SAS Institute, Cary, NC) using least
squares analysis. Leptin measurements for all ages sampled
of WT and activated TG mice were tested for differences
observed using a statistical model that included the fixed
effects of genotype and sex as well as the interaction be-
tween them. The data were then subdivided into juvenile (42
and 63 days) and mature (84 and 105 days) subgroups so
that the effects of transgene inactivation could be examined.
TG animals that had the transgene activated and then inac-
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tivated were only included at 84 and 105 days of age and
therefore could not be tested in the model inclusive of data
from samples obtained from 42- and 63-day mice. Splitting
the data allowed for the examination of factors important to
leptin expression between the juvenile and mature data sets.
Correlations of circulating leptin concentrations and leptin
expressed as a percentage of total body lipid with adipose
depot weights and total body lipid were performed using
correlation procedures of SAS (1988).
Results
To characterize circulating leptin concentrations as a
function of genotype, we first determined whether the zinc
supplementation affected leptin levels in WT mice. No
difference (p . 0.1) in plasma leptin concentration was
observed between WT animals and WT animals in which
the zinc (transgene) stimulus was withdrawn at any age
examined. Therefore, data for zinc-treated and untreated
WT mice were pooled for subsequent analyses. In compar-
ing WT and activated TG mice, circulating leptin concen-
trations were not significantly (p . 0.1) different between
these groups, with the exception of male animals at 42 days
of age (Table 1). However, when compared with either WT
or activated TG mice, plasma leptin concentrations from
inactivated TG mice were higher at both 84 and 105 days of
age (Table 1; p , 0.05).
In a multivariate regression model, circulating leptin con-
centrations over the four ages revealed that gender effects
(p , 0.0001) and the gender by age interaction (p , 0.05)
were significant. In comparison with males, plasma leptin
levels increased with age in the females. In addition, at each
age examined, plasma leptin concentrations in females were
higher than in males. This increase was statistically signif-
icant in older mice (p , 0.01) (Figure 1).
When the mature age group data (84 and 105 days of
age) were analyzed inclusive of the inactivated genotype
present at these ages, age by gender by genotype inter-
actions were significant (p , 0.0001). That is illustrated
by the plasma leptin concentrations for inactivated fe-
male TG mice. At 84 days and 105 days, female TG mice
in which the transgene was inactivated had leptin con-
centrations that were significantly elevated compared
with inactivated male TG mice (Table 1, p , 0.0001).
More important, female mice in which the transgene was
inactivated had significantly higher plasma leptin con-
centrations than either activated TG or WT genotypes
(p , 0.001); this was true only at 105 days of age for
male TG mice in which the transgene was inactivated.
However, circulating leptin concentrations for TG mice
were not significantly different from those of WT mice
within a given gender (p . 0.6 for both genotype com-
parisons).
In an effort to identify whether a particular fat depot was
highly correlated with circulating leptin concentrations,
body composition data for the mice used in this study as
published previously (8) were compared with the circulating
leptin values reported here. Parameters examined included
total body fat (TBF) and the weights of subcutaneous,
mesenteric, and gonadal fat pads. In both male and female
animals, plasma leptin concentrations were positively cor-
related with all adipose parameters at 84 and 105 days of
age, but not at 42 and 63 days of age (p , 0.05, Table 2).
Evidence exists that suggests that leptin concentrations
can vary independent of TBF, for example during energy
restriction (13,14). To investigate leptin levels adjusted for
TBF, circulating leptin concentrations were expressed as
per gram of TBF. Analysis of leptin adjusted for body fat
revealed a decrease with age (3.0 6 0.2, 1.5 6 0.2, 1.2 6
0.2, and 1.0 6 0.2 ng/mL per gram for 43, 63, 84, and 105
days, respectively, p , 0.005). In addition, females gener-
ally had higher adiposity-adjusted leptin levels than males,
and perhaps most important, female WT animals had greater
amounts of leptin per gram of TBF than either activated TG
or inactivated TG females at 84 and 105 days of age; this
tendency was also observed for male WT animals (Table 1
and Figure 2).
Discussion
In this study, female mice had consistently higher plasma
levels of leptin than male mice regardless of treatment. This
result concurs with previous studies on gender differences
in plasma leptin concentrations in humans (15,16). The
most important result was that animals in which the trans-
gene was no longer actively expressing GH had signifi-
cantly higher leptin values than continuously activated TG
or WT control mice. In both female and male mice in which
the transgene was inactivated, plasma leptin concentrations
were three times higher than those of WT animals of the
same gender. This difference was likely due to the enlarged
adipose depots (300% greater than control mice) in these
mice after the high expression of the GH transgene ceases
(8). While leptin significantly correlated with all measures
of fat at 84 and 105 days of age, it remains unexplained why
the inactivated TG animals, who gain 300% more adipose
tissue than WT control animals, do not adjust physiologi-
cally by decreasing food intake or increasing energy expen-
diture, which might be expected in response to increasing
plasma leptin concentrations.
Leptin regulation is more complex than a simple reflec-
tion of adipose stores. The response of leptin to nutritional
factors such as fatty acids and glucose, its diurnal expres-
sion patterns (17), and its diverse functions (6,7) are signs of
this complexity. Although leptin itself may exert some
autocrine/paracrine effect on isolated adipocytes (18), indi-
rect effects of leptin may be regulated through the hypo-
thalamic–pituitary axis or through activation of autonomic
(sympathetic) outflow (19,20). In the present study, plasma
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leptin levels appear to be uncoupled from their physiolog-
ical effects in inactivated TG mice.
The development of obesity in the face of elevated leptin
in mice in which the GH transgene was inactivated was
unexpected. The GH transgene is not expressed at the same
time that visible obesity develops in these mice. Therefore,
the actual accrual of adipose tissue must involve down-
stream effects of the transgene GH expression responsible
for the capacity to become obese. Oberbauer et al. (8) have
previously published data on the body composition of the
mice used in this study (up to 105 days of age). They found
that the obese phenotype that occurs in these TG mice does
not appear to depend on insulin resistance, development of
diabetes, or decreased brown fat thermogenic capacity. It
Figure 1. Circulating leptin concentrations (nanograms per milliliter) in male (hatched bars) and female (open bars) mice pooled across
genotypes at varying ages. Values are expressed as least squares means 6 SEM and asterisks denote significant (p , 0.05) differences
between males and females.
Table 2. Correlation coefficients (and significance levels*) for circulating leptin with TBF, gonadal fat pad,
mesenteric fat pad, and inguinal fat pad weights for male and female mice pooled across genotypes at varying ages
TBF GFP MFP IFP
Males
42 days 20.68 (p , 0.005) NS* NS NS
63 days NS NS NS NS
84 days 0.68 (p , 0.001) 0.68 (p , 0.001) 0.70 (p , 0.001) 0.60 (p , 0.001)
105 days 0.63 (p , 0.001) 0.60 (p , 0.001) 0.65 (p , 0.001) 0.62 (p , 0.001)
Females
42 days NS NS 20.57 (p , 0.02) 20.51 (p , 0.04)
63 days NS NS NS NS
84 days 0.86 (p , 0.001) 0.88 (p , 0.001) 0.84 (p , 0.001) 0.84 (p , 0.001)
105 days 0.84 (p , 0.001) 0.78 (p , 0.001) 0.79 (p , 0.001) 0.76 (p , 0.001)
GFP, gonadal fat pad; MFP, mesenteric fat pad; IFP, inguinal fat pad.
* NS, nonsignificant (p . 0.1).
Plasma Leptin in oMT1a-oGH Transgenic Mice, Oberbauer et al.
OBESITY RESEARCH Vol. 9 No. 1 January 2001 55
would seem plausible that chronically high GH levels do
result in leptin resistance mediated through the hypothala-
mus by decreased receptor sensitivity or leptin transport.
Our activated TG mice have chronically high GH levels.
Physiologically, these mice may decrease hypothalamic
sensitivity to leptin as an attempt to decrease perceived
continued pituitary release of GH. It is not clear why this
resistance would persist past 63 days when the high-level
expression of the transgene is terminated in inactivated TG
mice. However, in GH-deficient human patients, higher
than expected plasma concentrations of leptin are seen (21),
although this may reflect the enlarged adipose mass that
accompanies GH deficiency. It is unclear in many patients
whether this is the result of GH deficiency or decreased
sensitivity to plasma leptin (22). In these human patients
and in the mice with the inactivated transgene in this study,
leptin resistance may impair the release of adequate GH
from the pituitary (23,24).
Hormonal control of adipocyte function may be an im-
portant determinant of leptin expression; however, long-
term basal leptin expression may actually be more closely
correlated with indices of fat cell size. In some experiments,
plasma leptin has been tightly correlated with fat cell size
(25). Oberbauer et al. (8) demonstrated that WAT increases
up to 270% by 105 days of age after transgene inactivation
at maturity (63 days of age). The adipose tissue in these
animals is composed of cells that are both larger and more
numerous. It is expected that with increasing adipocyte cell
number and/or size, leptin levels would increase corre-
spondingly. In the oMT1a-oGH model, inactivated TG mice
had more numerous small fat cells and the male inactivated
TG mice had a greater number of large adipocytes, whereas
the female inactivated TG mice had significantly larger
large adipocytes. Because the effect of high GH levels is to
negate the difference in growth rate between males and
females in this model, female TG mice put on proportion-
ally more lean body mass over control females than male
TG mice do over control males. This dimorphic response
may represent a greater reserve growth potential or it may
represent a differential sensitivity to the effects of elevated
GH. In the latter case, females may be stretched closer to
their genetic capacity under the influence of TG GH expres-
sion. Males may thus have more immediate resources avail-
able to produce more preadipocytes than do females who
are putting more energy into developing lean body mass
over the period of transgene expression from 21 to 63 days
in this experiment. A large number of large-sized cells may
yield relatively low leptin values (males), whereas a low
number of very large cells yields high plasma leptin con-
centrations (females). This is supported by the data of leptin
expressed on a per gram of TBF basis. Male inactivated TG
mice had much lower adjusted leptin levels when compared
with the data from the female inactivated TG mice.
Alternatively, leptin levels may not literally represent the
amount of body fat but rather may be related to adipocyte
cell membrane stretching or adipocyte glucose metabolism
(26). It is interesting to note that Murray et al. (27) reported
that expression of the oMT1a-oGH transgene results in
altered cell membrane composition. Some membrane-asso-
ciated compounds may be related to the signaling process
involved in leptin expression or to the physiological re-
sponse of adipocytes to inhibitory signals resulting from
leptin activity. The cell membrane components may be
altered in the oMT1a-oGH model.
Jorgensen et al. (28) found that leptin was an important
determinant of resting basal metabolic rate (BMR). Long-
term GH therapy in human subjects induces a new energy
balance state characterized by the return of depressed
plasma leptin concentrations to basal levels and by in-
creased BMR. Body fat in these subjects remains reduced
and indicates that a new energy balance is achieved (29).
Unfortunately, Karlsson et al. (29) did not examine leptin
and BMR in a post-therapy state in which the opposite could
be predicted to be true (i.e., elevated leptin and decreased
BMR). The TG mice in this study also appear to have
established a new postinactivation steady state of energy
balance that has been triggered by TG GH expression. The
nature of this interaction needs to be investigated.
In this study, we examined the plasma concentrations of
leptin in both sexes of mice that demonstrate an obese
phenotype on cessation of high levels of transgene GH
expression. We have shown that plasma leptin concentra-
tions in the obese inactivated TG mice follow predicted
patterns with regard to gender, genotype, and age. However,
examining the amount of leptin produced per gram of body
fat indicates a significant reduction in the amount of leptin
secreted per gram of lipid in animals subjected to elevated
concentrations of GH (activated TG) and in animals in
which the elevated GH has been removed (inactivated TG).
Figure 2. Circulating leptin expressed per gram of TBF for WT
(hatched bars), TG (gray bars), and inactivated TG (striped bars)
pooled male and female mice at varying ages. Values are ex-
pressed as least squares means 6 SEM and asterisks denote
significant (p , 0.05) differences from the WT genotype.
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It is possible that the elevated GH alters glucose utilization
in the adipose cell by promoting insulin resistance. The
activated TG mice have elevated circulating insulin concen-
trations without alteration of circulating glucose levels, sug-
gesting that these animals are experiencing insulin resis-
tance (8). Decreased glucose utilization is known to depress
leptin secretion by the adipocyte (6,7). Although we have
not directly measured glucose metabolism in adipocytes
from animals exposed to elevated GH, it is well known that
excess GH can induce insulin resistance. It is possible that
the lowered leptin production on a per gram of fat basis is
due to a decrease in insulin-mediated glucose metabolism
within adipose tissue. If adipose tissue is using less glucose,
the production of leptin would be diminished (6,7). If this
were the case for the activated TG animal, the elevated GH
would serve to prevent excess fat deposition; however, on
withdrawal of the elevated GH, as seen in the inactivated
TG, the lower leptin on a per gram fat basis would no longer
be counterbalanced by the elevated GH and the obese phe-
notype could develop as the adipocytes hypertrophy.
The data suggest that normal physiological responses to
elevated plasma leptin are impaired in response to pro-
longed elevation of GH. Although the most likely site of
impairment is in the hypothalamic axis (leptin resistance),
GH effects at the adipocyte cellular level are also possible
particularly because a number of adipocyte characteristics
are altered by GH transgene expression (e.g., cell size,
number, and membrane composition) (8,27). One of the
most important factors in the production of the obese phe-
notype must be the recruitment and differentiation of prea-
dipocytes. We have shown that GH causes an obese phe-
notype as well as the development of an abnormal
physiological response to increasing plasma leptin concen-
trations. The results of the present study suggest that alter-
ations of leptin production and action induced by overex-
pression of GH contribute to increased adiposity in
this model.
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